Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

12,957 total articles

ZenaTech Expands Drone as a Service Platform with 24th Acquisition, Adding Green Earth Powerwashing Franchise Network

ZenaTech Expands Drone as a Service Platform with 24th Acquisition, Adding Green Earth Powerwashing Franchise Network

ZenaTech, a Nasdaq-listed technology company specializing in AI-powered drones and Drone as a Service (DaaS), has acquired Green Earth Powerwashing LLC, a Florida-based franchise providing exterior cleaning and property maintenance services. This 24th acquisition strengthens ZenaTech's footprint in Florida and integrates drone-powered cleaning into…

From the pitch to the airport: Cristiano Ronaldo and Vini Jr. chosen as Brazil’s dream travel buddies, reveals KAYAK

From the pitch to the airport: Cristiano Ronaldo and Vini Jr. chosen as Brazil’s dream travel buddies, reveals KAYAK

KAYAK, a travel search engine under Booking Holdings, surveyed 2,000 Brazilian travelers to identify which football players they most want to travel with, with Cristiano Ronaldo leading at 60%. The Northeast region of Brazil, particularly Bahia, was the preferred destination. The survey insights aim to influence travel plans and promote destination…

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling

Kalaris Therapeutics, a clinical-stage biopharmaceutical company, announced it will present Phase 1a clinical data of its novel dual-targeting biologic TH103 at the American Society of Retina Specialists 2026 Annual Meeting. The company is actively enrolling patients in its Phase 1b/2 trial for TH103 targeting neovascular Age-related Macular Degene…

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics announced positive feedback from its Type C meeting with the FDA, securing agreement on the primary endpoint and regulatory path for belapectin's Phase 3 trial targeting metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension. The Phase 3 protocol filing is planned for Q3 2026, with strategic …

ASP Isotopes Inc. Announces that a Subsidiary of Renergen Limited Has Entered into its First Take-or-Pay Contract for the Supply of Contained Helium to be Produced at the Virginia Gas Project in South Africa

ASP Isotopes Inc. Announces that a Subsidiary of Renergen Limited Has Entered into its First Take-or-Pay Contract for the Supply of Contained Helium to be Produced at the Virginia Gas Project in South Africa

ASP Isotopes Inc. announced that its subsidiary Renergen Limited's Tetra4 has entered into its first five-year take-or-pay contract to supply contained helium to an Asian industrial gases company from the Virginia Gas Project in South Africa. Phase 1 commercial operations remain targeted for Q3 2026, with helium sales priced above $600/MCF. Phase 2…

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification

IMUNON announced that the independent Data Monitoring Committee has recommended continuation of its pivotal Phase 3 OVATION 3 study evaluating IMNN-001 in advanced ovarian cancer patients without any modifications. The trial remains on track to enroll approximately 80 patients by Q1 2027. The decision reflects the strong safety and efficacy profile…

Veea Inc. and TROLLEE Holdings Ltd. Extend Strategic Partnership to Deliver a Highly Advanced AI-Powered Autonomous Retail Ecosystem

Veea Inc. and TROLLEE Holdings Ltd. Extend Strategic Partnership to Deliver a Highly Advanced AI-Powered Autonomous Retail Ecosystem

Veea Inc. (NASDAQ: VEEA) and TROLLEE Holdings Limited have extended their strategic partnership to develop an advanced AI-driven autonomous retail ecosystem. The collaboration integrates Veea's edge-AI infrastructure with TROLLEE's smart shopping carts and retail robotics to enable fully autonomous stores that enhance inventory management, security…

64% of UK Consumers Want to Use Agentic AI for Shopping, According to New Research from Commerce and PayPal

64% of UK Consumers Want to Use Agentic AI for Shopping, According to New Research from Commerce and PayPal

Commerce and PayPal released a research study revealing 64% of UK consumers are interested in using agentic AI tools for shopping, which assist in product research, comparison, and purchasing. While adoption is nascent, most consumers desire AI to facilitate better deals and discounts but prefer to retain control over purchase decisions. The study …

VisionWave Unveils Combat-Ready TALON™ and D-FLY™ Autonomous Drone Platforms at Eurosatory 2026, Expanding STRATUM™ Battlefield Autonomy Ecosystem

VisionWave Unveils Combat-Ready TALON™ and D-FLY™ Autonomous Drone Platforms at Eurosatory 2026, Expanding STRATUM™ Battlefield Autonomy Ecosystem

VisionWave Holdings, Inc. introduced two new autonomous drone platforms, TALON™ Tactical Autonomous Aerial System and D-FLY™ Autonomous Intercept Platform, at Eurosatory 2026. These platforms expand VisionWave's STRATUM™ battlefield autonomy ecosystem, demonstrating integrated AI-driven autonomous capabilities for ISR, counter-UAS, communications r…

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

Revolution Medicines Begins Treating Patients in RASolute 305, a Phase 3 Clinical Trial Evaluating Zoldonrasib in Combination with Chemotherapy as a First Line Treatment for Patients with RAS G12D Metastatic Pancreatic Cancer

Revolution Medicines has announced the commencement of patient treatment in RASolute 305, a global Phase 3 randomized trial evaluating zoldonrasib combined with standard chemotherapy as a first-line treatment in metastatic RAS G12D pancreatic ductal adenocarcinoma (PDAC). Building on previous positive data with their RAS(ON) inhibitors, this trial …

Airship AI Secures Seven Figure Follow-On Contract Award with Fortune 100 Transportation & E-Commerce Company

Airship AI Secures Seven Figure Follow-On Contract Award with Fortune 100 Transportation & E-Commerce Company

Airship AI Holdings announced a significant one-year contract extension worth $1.9 million with an existing Fortune 100 transportation and e-commerce client for maintenance and sustainment of its Acropolis Enterprise Video and Data Management platform. The company also received additional smaller orders totaling $1.4 million, enhancing its recurrin…

Two-Thirds of Consumers Are Ready to Try Agentic Shopping, but Many Demand Human Approval Before AI Can Buy

Two-Thirds of Consumers Are Ready to Try Agentic Shopping, but Many Demand Human Approval Before AI Can Buy

Commerce (Nasdaq: CMRC) released a research study revealing that two-thirds of consumers across the US, UK, and Australia are interested in trying AI-powered agentic shopping tools that assist with product discovery, comparison, and purchasing. While enthusiasm is high, consumers emphasize the need for transparency, security, and human approval in …

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

INmune Bio Receives MHRA Written Alignment Supporting Planned 2026 UK Conditional Marketing Authorization Application for CORDStrom™ in RDEB

INmune Bio secured written alignment from the UK MHRA on its development and regulatory strategy for CORDStrom™ (Ebstrocel™) targeting Recessive Dystrophic Epidermolysis Bullosa (RDEB). The guidance clarifies manufacturing, safety, and clinical evidence requirements and supports a 2026 conditional marketing authorization submission in the UK, with …

Integra LifeSciences Announces Key Executive Appointments

Integra LifeSciences Announces Key Executive Appointments

Integra LifeSciences Corporation Holdings announced a series of leadership changes within its commercial organization, including new appointments and promotions aimed at enhancing customer focus, accelerating execution, and supporting the company’s long-term growth strategy. These changes involve executives leading key divisions such as Tissue Reco…

Provident Bank Appoints Adriano Duarte EVP and Chief Financial Officer

Provident Bank Appoints Adriano Duarte EVP and Chief Financial Officer

Provident Bank appointed Adriano Duarte as Executive Vice President and Chief Financial Officer, effective July 1, 2026. Duarte, with over 30 years of banking experience, previously served as EVP and Chief Accounting Officer and will lead key financial functions to support growth and financial performance at Provident Bank and its parent company, P…

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals Completes Patient Enrollment Ahead of Schedule in Phase 2 pHalcon-EoE-201 Study of VOQUEZNA® (vonoprazan) in Eosinophilic Esophagitis (EoE)

Phathom Pharmaceuticals announced early completion of patient enrollment for its Phase 2 pHalcon-EoE-201 clinical trial assessing VOQUEZNA® (vonoprazan) as a potential treatment for eosinophilic esophagitis (EoE). The double-blind, placebo-controlled study enrolled 95 adult patients across 41 U.S. sites, with topline results expected in Q4 2026. Po…

Edible Garden Secures Up to $6.3 Million in Local Development Incentives to Support Webster City Clean Nutrition Manufacturing Hub

Edible Garden Secures Up to $6.3 Million in Local Development Incentives to Support Webster City Clean Nutrition Manufacturing Hub

Edible Garden AG Incorporated announced a development agreement securing up to $6.3 million in tax increment financing incentives from Webster City to support the redevelopment and expansion of its Prairie Hills facility into a large-scale ready-to-drink (RTD) beverage production hub. This investment builds upon a previous $2.66 million incentive f…

Quantum Cyber Unveils Quantum Station: A Battlefield Operating System for Multi-Domain Autonomous Warfare

Quantum Cyber Unveils Quantum Station: A Battlefield Operating System for Multi-Domain Autonomous Warfare

Quantum Cyber N.V. (Nasdaq: QUCY) unveiled Quantum Station, a rugged, integrated battlefield operating system designed to unify drone command-and-control across air, land, and sea domains. The system consolidates hardware, software, and communication layers into a portable, secure platform that supports multiple drone protocols and operates in cont…